U.S., Oct. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07215312) titled 'A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin' on Oct. 09.
Brief Summary: The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Diabetes Mellitus, Type 2
Intervention:
DRUG: LY3938577
Administered SC
DRUG: Degludec
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Disclaimer: Curated by HT Syndication....